Softbank Group CORP. Sells 1,005,726 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Softbank Group CORP. cut its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 13.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,541,190 shares of the company's stock after selling 1,005,726 shares during the quarter. Neumora Therapeutics accounts for 0.3% of Softbank Group CORP.'s investment portfolio, making the stock its 12th biggest holding. Softbank Group CORP. owned approximately 4.05% of Neumora Therapeutics worth $69,337,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its position in Neumora Therapeutics by 2.6% during the third quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company's stock worth $851,000 after acquiring an additional 1,629 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Neumora Therapeutics during the fourth quarter worth about $363,000. SkyOak Wealth LLC grew its position in Neumora Therapeutics by 33.3% in the fourth quarter. SkyOak Wealth LLC now owns 20,000 shares of the company's stock valued at $212,000 after acquiring an additional 5,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Neumora Therapeutics during the 4th quarter valued at $61,000. Finally, Windmill Hill Asset Management Ltd increased its position in shares of Neumora Therapeutics by 299.6% during the fourth quarter. Windmill Hill Asset Management Ltd now owns 104,373 shares of the company's stock worth $1,106,000 after acquiring an additional 78,252 shares during the last quarter. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $5.00 target price on shares of Neumora Therapeutics in a report on Tuesday, May 13th. Stifel Nicolaus cut shares of Neumora Therapeutics from a "buy" rating to a "hold" rating and decreased their target price for the stock from $6.00 to $2.00 in a research report on Friday, March 7th. Royal Bank of Canada reissued a "sector perform" rating and issued a $4.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, March 4th. HC Wainwright reduced their price target on Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Finally, Guggenheim downgraded shares of Neumora Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, March 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $9.29.

Neumora Therapeutics Stock Performance

Shares of NASDAQ:NMRA traded up $0.02 during midday trading on Wednesday, reaching $0.75. The company had a trading volume of 564,982 shares, compared to its average volume of 1,504,576. The company has a fifty day simple moving average of $0.82 and a two-hundred day simple moving average of $4.15. The firm has a market cap of $121.31 million, a price-to-earnings ratio of -0.40 and a beta of 2.96. Neumora Therapeutics, Inc. has a 1-year low of $0.61 and a 1-year high of $17.19.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.02). Analysts expect that Neumora Therapeutics, Inc. will post -1.61 EPS for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.